


# Sacubitril/valsartan shows benefit in heart failure with ejection fraction above 40%

May 21 2023

---



Credit: Unsplash/CC0 Public Domain

Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF) above 40%, according

to late breaking science presented today at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC), and published in the *Journal of the American College of Cardiology*.

Principal investigator Dr. Robert Mentz of Duke University Medical Center, Durham, US said, "These data add to the evidence supporting a potential treatment benefit of sacubitril/valsartan in patients with EF over 40% and particularly in those with EF below normal (

Citation: Sacubitril/valsartan shows benefit in heart failure with ejection fraction above 40% (2023, May 21) retrieved 10 May 2024 from

<https://medicalxpress.com/news/2023-05-sacubitrilvalsartan-benefit-heart-failure-ejection.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.